Novartis bone marrow cancer drug meets goal in late-stage study

December 6, 2013 10:06 AM

11 0

Novartis bone marrow cancer drug meets goal in late-stage study

ZURICH (Reuters) - An experimental drug from Novartis to treat a type of bone marrow cancer met its primary goal in a late-stage study, the Swiss drugmaker said on Friday.

A Phase III trial found the drug, dubbed LBH589 when combined with bortezomib and dexamethasone, significantly extended progression-free survival in patients with relapsed or relapsed and refractory multiple myeloma compared to bortezomib and dexamethasone alone.

Read more

To category page

Loading...